In order to advance science and improve patient care with CSL Behring's products in the area of immunoglobulin research, we support, with provision of drug and/or total or partial funding, high-quality research that is initiated, designed, implemented, and sponsored by external investigators and is involved with the immunoglobulin products Privigen® (Immune Globulin Intravenous (Human) 10% Liquid) and/or Hizentra® (Immune Globulin Subcutaneous (Human) 20% Liquid). Support is provided based on the scientific merit of the proposal as well as alignment with the following specific areas of interest:
Primary Immunodeficiency (PID)
Proposals that increase the knowledge of the efficacy and safety of the immunoglobulins in PID indications, specifically route of administration, subclinical infections in diagnosed PID patients with respiratory tract engagement, quality of life, wear-off, manual push, flexible dosing/patient preference, and undiagnosed PID.
Secondary Immune Deficiency (SID)
Proposals that increase the knowledge of immunoglobulins in regard to efficacy and safety, specifically the combination of immunoglobulins with products that cause drug-induced SID in conditions such as multiple myeloma and chronic lymphocytic leukemia (CLL).
Proposals that increase the knowledge of efficacy and safety of the and pediatric patients.
Hizentra and Privigen are manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® and Privigen® are registered trademarks of CSL Behring AG.
CSL Behring is committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in the support for Investigator-Initiated Studies (IIS) that advance medical and scientific knowledge of CSL Behring products and the diseases they are designed to treat. CSL Behring also supports innovative clinical and basic science studies that address important medical and scientific questions related to our therapeutic areas of focus.
Areas of Focus
- Haemophilia Disorders
- Immune-mediated Neuromuscular Disorders
- Acquired & Oral Anticoagulant-Associated Bleeding
- Hereditary Angioedema (HAE)
The link below is for US physicians, researchers and institutions interested in conducting their own research. For those outside the US, contact your local CSL Behring Medical Affairs representative. We receive many requests for support and carefully evaluate each one. Priority is given to proposals that align with our interests.
Disclaimer: All materials submitted as IIS application must be non-confidential. By submitting an IIS application, you acknowledge that CSL Behring is under no obligation of confidentiality with respect to materials submitted.